Appointed CEO; Current Chief Business Development and Strategy Officer
Kyle Gano is the Chief Business Development and Strategy Officer at Neurocrine Biosciences, a neuroscience-focused, biopharmaceutical company. Responsible for business and corporate development activities at Neurocrine for more than 18 years, Mr. Gano manages ongoing strategic collaborations to support a diverse pipeline of programs across multiple therapeutic areas to help bring life-changing treatments to patients with neurological, endocrine and psychiatric disorders.
Dr. Gano is responsible for the management of ongoing collaborations with Takeda Pharmaceuticals, AbbVie, BIAL, Mitsubishi Tanabe Pharma, Voyager Therapeutics, Idorsia, Xenon, and Sumitomo Dainippon Pharma. From 2001 to 2011 he held several positions of increasing responsibility at Neurocrine spanning Marketing Analytics to Business Development. Dr. Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and M.B.A. in Finance from the University of California, Los Angeles.